Compare IHG & VTRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | IHG | VTRS |
|---|---|---|
| Founded | 1777 | 1961 |
| Country | United Kingdom | United States |
| Employees | N/A | N/A |
| Industry | Hotels/Resorts | Medicinal Chemicals and Botanical Products |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 17.0B | 14.2B |
| IPO Year | N/A | N/A |
| Metric | IHG | VTRS |
|---|---|---|
| Price | $137.42 | $12.82 |
| Analyst Decision | Hold | Hold |
| Analyst Count | 3 | 6 |
| Target Price | N/A | ★ $11.50 |
| AVG Volume (30 Days) | 189.1K | ★ 9.3M |
| Earning Date | 08-02-2016 | 02-26-2026 |
| Dividend Yield | 1.23% | ★ 3.65% |
| EPS Growth | ★ 21.99 | N/A |
| EPS | ★ 4.70 | N/A |
| Revenue | $5,120,000,000.00 | ★ $14,124,400,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $6.29 | $1.18 |
| P/E Ratio | $29.09 | ★ N/A |
| Revenue Growth | ★ 33.89 | N/A |
| 52 Week Low | $94.78 | $6.85 |
| 52 Week High | $144.96 | $13.49 |
| Indicator | IHG | VTRS |
|---|---|---|
| Relative Strength Index (RSI) | 49.21 | 63.74 |
| Support Level | $135.48 | $12.53 |
| Resistance Level | $139.44 | $13.49 |
| Average True Range (ATR) | 2.31 | 0.31 |
| MACD | -0.79 | 0.01 |
| Stochastic Oscillator | 43.70 | 48.85 |
InterContinental Hotels Group operates 987,000 rooms across 19 brands addressing the midscale through luxury segments, as of Dec. 31, 2024. Holiday Inn and Holiday Inn Express constitute the largest brand, while Hotel Indigo, Even, Hualuxe, Kimpton, and Voco are newer lifestyle brands experiencing strong demand. The company launched a midscale brand, Avid, in 2017 and closed on a 51% stake in Regent Hotels in 2018. It acquired Six Senses in 2019 and launched another midscale brand, Garner, in 2023. Managed and franchised represent 99% of total rooms. As of Dec. 31, 2024, the Americas represented 53% of total rooms, with Greater China accounting for 20% and Europe, Asia, the Middle East, and Africa making up 27%.
Viatris was formed in November 2020 through the combination of Upjohn, a wholly owned subsidiary of Pfizer that specialized in off-patent drugs, and Mylan, a global pharmaceutical manufacturer that focused on generic and specialty drugs. By joining forces, Viatris became one of the largest generic drug manufacturers in the world, servicing over 165 countries. Generics (commoditized and complex) and biosimilars make up roughly 40% of Viatris' total sales. The remaining 60% of sales are derived from its portfolio of legacy products, which includes Lipitor, Norvasc, Lyrica, and Viagra. While it covers more than 10 major therapeutic areas, Viatris has identified dermatology, ophthalmology, and gastroenterology as its three key areas of focus for future innovations.